![]() ![]() The objective of this study was to evaluate adherence to institution restriction criteria and the clinical outcomes of treatment for patients for whom andexanet alfa is requested. ![]() boxed warning, cost of up to $58,000 per dose, and limited efficacy data compared with standard of care, hospitals are faced with a dilemma with its addition to formulary and process for ensuring optimized use. Given its novel mechanism of action, U.S. The ANNEXA-4 study was successful in reducing factor Xa levels during time of administration but lacked correlation to improved patient outcomes. The work cannot be changed in any way or used commercially without permission from the journal.Īndexanet alfa is the first approved antidote in the management of life-threatening bleeds in patients treated with Xa inhibitors. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. ![]() The authors have disclosed that they do not have any potential conflicts of interest.įor information regarding this article, E-mail: Choi and Opsha were responsible for conception and design, analysis and interpretation, and editing the article with final approval of submission. Sobolewski and Brophy were responsible for conception and design, analysis and interpretation, and drafting the article with final approval of submission. This work was performed at Saint Barnabas Medical Center, RWJ-Barnabas Health System, 94 Old Short Hills Road, Livingston NJ 07039.ĭrs. ![]() 1 Department of Pharmacy, Saint Barnabas Medical Center, Livingston, NJ.Ģ Ernest Mario School of Pharmacy-Rutgers University, Livingston, NJ. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |